Sign in

HCTI on Nasdaq

Healthcare Triangle, Inc.

Healthcare Triangle, Inc. is an American computer integrated systems design services company.2 It is headquartered in Pleasanton, United States.2 Its shares trade on Nasdaq under the symbol HCTI.2

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with Borqs Technologies, Inc., Super League Enterprise, Inc. or TuSimple, or pick any stock.

  • TickerHCTI on Nasdaq2
  • IndustryServices-Computer Integrated Systems Design2
  • HeadquartersPleasanton, United States2
  • Incorporated inDE3
  • Business address7901 Stoneridge Drive, Suite 210, Pleasanton, Ca 945883
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI549300KKBM83T87VHO352
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O HARVARD BUSINESS SERVICES, INC., 19958 Lewes, United States2
  • Registered withDivision of Corporations, Department of State, 79496342

See how the biggest companies compare on our leaderboards

Combined with our software and solutions, our services provide clients with an end-to-end partnership for their technology innovation.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

8890.6%Gross margin5
-70.5%Operating margin5
-68.2%Net margin5
18.8%Revenue growth, 20255
-95.3%Return on equity5
-$16.5MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Software Services brought in 58% of the revenue Healthcare Triangle, Inc. broke down this way in fiscal 2025.

  1. Software Services$8.3M558%up 76% from 2024
  2. Managed Services And Support$5.4M538%down 20% from 2024
  3. Corporate And Others$278.0K52%down 3% from 2024
  4. Corporate Others$278.0K52%down 3% from 2024
Products and services by year
Products and services20242025
Software Services$4.7M$8.3M
Managed Services And Support$6.7M$5.4M
Corporate And Others$288.0K$278.0K
Corporate Others$288.0K$278.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue86¢$12.0M
  • Research and development4¢$536.0K
  • Other costs6¢$787.0K
  • Interest4¢$567.0K

Out of $13.9M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$13.9M in 2025−56% since 2020
0$20.0M$40.0M$60.0M2020: $31.3M$31.3M20202021: $35.3M$35.3M2021+13%2022: $45.9M$45.9M2022+30%2023: $33.2M$33.2M2023−28%2024: $11.7M$11.7M2024−65%2025: $13.9M$13.9M2025+19%
Gross profit895$1.2B in 2025+15% since 2023
0$500.0M$1.0B$1.5B2023: $1.1B$1.1B20232024: $1.1B$1.1B2024+0%2025: $1.2B$1.2B2025+15%
Operating income67895-$9.8M in 2025
-$20.0M-$15.0M-$10.0M-$5.0M0$5.0M2020: $1.2M$1.2M20202021: -$5.4M-$5.4M20212022: -$16.3M-$16.3M2022+205%2023: -$7.7M-$7.7M2023−53%2024: -$4.8M-$4.8M2024−38%2025: -$9.8M-$9.8M2025+106%
Net income67895-$9.5M in 2025
-$15.0M-$10.0M-$5.0M0$5.0M2020: $2.4M$2.4M20202021: -$5.9M-$5.9M20212022: -$14.4M-$14.4M2022+141%2023: -$8.7M-$8.7M2023−40%2024: -$6.0M-$6.0M2024−31%2025: -$9.5M-$9.5M2025+59%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Net revenue$13.9M$11.7M
Cost of revenue (exclusive of depreciation and amortization shown separately below)$12.0M$8.8M
Gross margin$1.9M$2.9M
Sales and marketing$3.1M$2.2M
General and administrative$7.3M$4.0M
Research and development$536.0K$429.0K
Bad debts expense$17.0K$170.0K
Depreciation and amortization$705.0K$889.0K
Total operating expenses$11.7M$7.6M
Loss from operations-$9.8M-$4.8M
Other income$857.0K$7.0K
Changes in fair value$41.0K
Forex loss-$18.0K
Interest expense-$567.0K-$1.2M
Loss before income tax-$9.5M-$6.0M
Provision for income tax-$12.0K
Net loss-$9.5M-$6.0M
Foreign currency translation gain$11.0K
Deemed dividend-$7.4M
Comprehensive loss-$9.5M-$13.4M
Stockholders-$9.4M-$13.4M
Non-controlling interest-$37.0K
Stockholders (in Dollars per share)-$152.30-$16,909.30
Stockholders - diluted (in Dollars per share)-$152.30-$16,909.30
Non-controlling interest - basic (in Dollars per share)-$1
Non-controlling interest - diluted (in Dollars per share)-$1
Basic (in Shares)61.9K shares353 shares
Diluted (in Shares)61.9K shares353 shares

Compare Healthcare Triangle, Inc. with another company

Corporate structure

Healthcare Triangle, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Healthcare Triangle, Inc.

  • Healthcare Triangle, Inc. Pleasanton, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Healthcare Triangle, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$67.0K5 Dec 31, 2025$69.0K5 Dec 31, 2024−2.9%
Accumulated depreciation$62.0K5 Dec 31, 2025$57.0K5 Dec 31, 2024+8.8%
Property and equipment, net$5.0K5 Dec 31, 2025$12.0K5 Dec 31, 2024−58.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$7.6M5 Dec 31, 2025$20.0K5 Dec 31, 2024+38025.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$2.9M5 Dec 31, 2025$1.3M12 Dec 31, 2022+128.5%
Finite-lived intangibles, gross$3.5M5 Dec 31, 2025$14.3M9 Dec 31, 2024−75.4%
Accumulated amortization$710.0K5 Dec 31, 2025$14.3M9 Dec 31, 2024−95.0%
Finite-lived intangibles, net$2.8M5 Dec 31, 2025$857.0K9 Dec 31, 2023+227.7%

Inventory

ItemLatestA year beforeChange
Work in process$3.0K5 Dec 31, 2025$2.0K5 Dec 31, 2024+50.0%

Properties, in its own words

We lease and maintain our primary offices at 7901 Stoneridge Drive, Suite # 210 Pleasanton CA, USA 94588. We also have our satellite lease offices at 666 Plainsboro Road, Suite 448, Plainsboro, NJ 08536. We currently do not own any real estate.

Item 2 of the 10-K filed Apr 15, 2026.4

Leadership

Who has led Healthcare Triangle, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Suresh Venkatachari2021–2022

Chief financial officer

  1. Thyagarajan Ramachandran2021–2025
2025
Board members and other officers (17)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Financial OfficerDavid Ayanoglou named Dec 3, 2025 to Jun 16, 202631
  • Chief Operating Officer, and DirectorSujatha Ramesh named Dec 3, 2025 to Jun 16, 202631
  • Independent DirectorJainal Bhuiyan named Dec 3, 2025 to Jun 16, 202631

Timeline

  1. Oct 2, 20268-K Listing notice or transfer32
  2. Sep 25, 20268-K Entered a material agreement33
  3. Sep 8, 20268-K Entered a material agreement34
  4. Jul 29, 20268-K Unregistered sale of shares; Regulation FD disclosure35
  5. Jul 20, 20268-K Shareholder vote36
  6. Jun 26, 20268-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed37
  7. Jun 15, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares38
  8. Apr 10, 20268-K Entered a material agreement39
  9. Apr 7, 20268-K Financial statements and exhibits40
  10. Mar 11, 20268-K Other events41
  11. Feb 27, 20268-K Entered a material agreement; Regulation FD disclosure42
  12. Feb 13, 20268-K Change to shareholders' rights; Bylaws or fiscal year changed; Other events43
  13. Oct 29, 2021New chief executive Suresh Venkatachari becomes CEO13
  14. Apr 27, 2020Founded Healthcare Triangle, Inc. is founded2

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($25.15) a share, on Nov 13, 2025.44

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

240 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 68 major events, 50 insider forms, 8 large holders, 2 private raises, 88 other. The latest 20:

  1. Oct 13, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  2. Oct 2, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  3. Oct 2, 20268-K CURRENT REPORT EDGAR
  4. Sep 30, 2026EFFECT EDGAR
  5. Sep 25, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
  6. Sep 25, 20268-K CURRENT REPORT EDGAR
  7. Sep 8, 20268-K CURRENT REPORT EDGAR
  8. Aug 13, 202610-Q QUARTERLY REPORT EDGAR
  9. Jul 29, 20268-K CURRENT REPORT EDGAR
  10. Jul 20, 20268-K CURRENT REPORT EDGAR
  11. Jul 16, 2026424B3 PROSPECTUS EDGAR
  12. Jul 15, 2026EFFECT EDGAR
  13. Jul 10, 2026S-1 REGISTRATION STATEMENT EDGAR
  14. Jul 9, 2026RW WITHDRAWAL REQUEST EDGAR
  15. Jul 6, 2026S-3 REGISTRATION STATEMENT EDGAR
  16. Jun 26, 2026DEF 14A DEFINITIVE PROXY STATEMENT EDGAR
  17. Jun 26, 20268-K CURRENT REPORT EDGAR
  18. Jun 16, 2026PRE 14A PRELIMINARY PROXY STATEMENT EDGAR
  19. Jun 16, 2026D EDGAR
  20. Jun 15, 20268-K CURRENT REPORT EDGAR

The 240 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jun 12, 2026Raised $4.2 million in a private offering of debt Form D: 8 investors so far Form D
  2. Nov 20, 2025Raised $15 million in a private offering of debt Form D: 2 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Bank Of Montreal /can/20,000$36.2K0.0%+10,000
Geode Capital Management, LLC11,975$21.7K0.0%−620
UBS Group AG8,859$16.0K0.0%−31,856
Tower Research Capital LLC (TRC)1,314$2.4K0.0%+520
Vanguard Capital Management LLC859$1.6K0.0%No change
Barclays PLC310$5610.0%New
Jpmorgan Chase & Co20$380.0%New
Danske Bank A/s1$20.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Healthcare Triangle, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHealthcare Triangle, Inc.1
  • CIK0001839285
  • Employer ID (EIN)84-35597764
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)7373 Services-Computer Integrated Systems Design1
  • SEC reviewing officeOffice of Technology, Division of Corporation Finance1
  • Business address7901 Stoneridge Drive, Suite 210, Pleasanton, CA 945881
  • Phone925-270-48121
  • Shares outstanding14,974,322 as of Aug 12, 202611
  • Public float$40.7M as of Jun 30, 20254
  • AuditorSRCO Professional Corporation, Richmond Hill, Ontario, Canada PCAOB ID 5828; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceJan 13, 20211
  • Filings261 in all: 8-K (63), CORRESP (21), 3 (18), 4 (18), 10-Q (15), 5 (12), S-1/A (10), UPLOAD (10)1
    All 43 form types

    EFFECT (9), DEF 14A (8), PRE 14A (7), 10-K (5), 8-K/A (5), S-1 (5), PRE 14C (4), S-3 (4), 10-K/A (3), 424B5 (3), D (3), DEF 14C (3), NT 10-Q (3), SCHEDULE 13G (3), SCHEDULE 13G/A (3), 424B3 (2), 424B4 (2), DRS (2), DRS/A (2), DRSLTR (2), S-3/A (2), 10-Q/A (1), 3/A (1), 4/A (1), 8-A12B (1), ARS (1), CERT (1), D/A (1), DEFR14A (1), FWP (1), NT 10-K (1), POS AM (1), RW (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Oct 13, 2026
    Latest 8-K (8-K) Oct 2, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, $0.00001 par valueHCTIThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks Healthcare Triangle, Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 43 risks under these headings, as written.4

  • Risks Related to Our Company
  • Competition with companies that have greater financial, technical, and marketing resources than we have could result in a loss of clients and/or a lowering of prices for our products, causing a decrease in our revenues and/or market share.
  • We are dependent on the continued availability of third-party hosting and transmission services. Loss of contractual relationship with operational issues with, or changes to the costs of, our third-party data center providers could harm our business, reputation, or results of operations.
  • SecureKloud could cease to provide us with services and as a result, our business could suffer.
  • As a “controlled company” under the Nasdaq Marketplace Rules, we may choose to exempt our Company from certain corporate governance requirements that could have an adverse effect on our public stockholders.
  • A significant inadvertent disclosure or breach of confidential and/or personal information we hold, or of the security of our or our customers’, suppliers’, or other partners’ computer systems could be detrimental to our business, reputation, and results of operations.
  • An inability to attract and retain highly skilled employees could adversely affect our business.
  • Defects or disruptions in our cloud software solutions could result in diminished demand for our platforms and services, a reduction in our revenues, and subject us to substantial liability.
  • We have experienced rapid growth, and if we fail to manage our growth effectively, we may be unable to execute our business plan.
  • We may be unable to successfully introduce new products or services or fail to keep pace with advances in technology.
  • Our business depends in part on our ability to establish and maintain additional strategic relationships.
  • Our sales cycle can be lengthy and unpredictable, which may cause our revenue and operating results to fluctuate significantly.
The other 32 risks
  • Our revenues have historically been concentrated among our top customers, and the loss of any of these customers could reduce our revenues and adversely impact our operating results.
  • Risks Related to Our Intellectual Property and Our Platforms and Services
  • Protection of certain intellectual property may be difficult and costly, and our inability to protect our intellectual property could reduce the value of our products and services.
  • We may be liable for infringing the intellectual property rights of others.
  • We may not be able to protect our intellectual property rights throughout the world.
  • Our use of third-party open-source software could negatively affect our ability to offer our products and services through our platforms and subject us to possible litigation.
  • Any failure to protect our intellectual property that is not registered could impair our business.
  • We are subject to numerous privacy and data security laws and related contractual requirements and our failure to comply with those obligations could cause us significant harm.
  • Risks Related to Our Industry
  • Markets for our products and services are highly competitive and subject to rapid technological change, and we may be unable to compete effectively in these markets.
  • Increased government involvement in healthcare could materially and adversely impact our business.
  • Consolidation in the healthcare industry could adversely impact our business, financial condition, and operating results.
  • We are subject to numerous regulatory requirements of the healthcare industry and is susceptible to a changing regulatory environment.
  • We may be directly and indirectly liable for its client’s non-compliance with laws and regulations addressing Electronic Health Records.
  • The Company and its products are subject to laws and regulations concerning privacy, information security, data protection, consumer protection, and protection of minors, and these laws and regulations are continually evolving. Our actual or perceived failure to comply with these laws and regulations could harm our business, financial condition, results of operations, reputation, or prospects.
  • The Company and its products are subject to laws and regulations concerning healthcare provider’s practices and patients’ information protection. Our actual or perceived failure to comply with these laws and regulations could harm our business, financial condition, results of operations, reputation, or prospects.
  • The Company and its products are subject to laws and regulations concerning electronic prescribing standards and the adoption of controlled substance electronic prescribing. Our actual or perceived failure to comply with these laws and regulations could harm our business, financial condition, results of operations, reputation, or prospects.
  • We may be subject to liability as a result of a failure or a perceived failure to comply with laws and regulations governing approval and reimbursement of claims by healthcare industry payers.
  • In the event our software platforms and solutions are found to be subject to FDA’s regulations and approval in connection with the certain types of medical devices our software integrates with, we may have to incur additional costs or be subjected to potential criminal and civil penalties in case of the actual or perceived failure of us to comply with such regulations.
  • We may have to incur material expenses in order to accommodate its client’s interoperability requests dictated by interoperability standards of exchange of health information.
  • There is significant uncertainty in the healthcare industry, both as a result of recently enacted legislation and changing government regulation, which may have a material adverse impact on the businesses of our hospital clients and ultimately on our business, financial condition, and results of operations.
  • We may not see the benefits from government funding programs initiated to accelerate the adoption and utilization of health information technology.
  • We may be subject to false or fraudulent claim laws.
  • If the healthcare information technology market fails to continue to develop as quickly as expected, our business, financial condition, and operating results could be materially and adversely affected.
  • If the demand for cloud-based solutions declines, particularly in the Life Sciences industry, our revenues could decrease, and our business could be adversely affected.
  • Unfavorable conditions in our industry or the U.S. economy, or reductions in information technology spending, could limit our ability to grow our business and negatively affect our operating results.
  • The market for our data analysis systems and software solutions is new and unproven and may not grow.
  • If our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.
  • Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
  • We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.
  • The elimination of personal liability against our directors and officers under Delaware law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses.
  • Our certificate of incorporation will designate the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
  • These broad market and industry fluctuations may materially adversely affect the market price of our common stock, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume of our common stock are low.

Legal proceedings

From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. We may in the future receive claims from third parties asserting, among other things, infringement of their intellectual property rights. Future litigation may be necessary to defend ourselves, our partners and our customers by determining the scope, enforceability and validity of third-party proprietary rights, or to establish our proprietary rights. The results of any future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us. To date, we have not been made aware of any actual, pending or threatened litigation against the Company.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48